Vicarious Surgical Successfully Completes In-Vivo Porcine Lab, Advancing Robotic Surgery System Development Toward 2026 Design Freeze

Vicarious Surgical (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026.

During the lab, surgeons independently completed key elements of a ventral hernia repair using Vicarious Surgical's pre-DV system as part of a limited-scope feasibility assessment. In parallel, the company executed a series of targeted technical evaluations designed to assess system performance against key engineering and functional specifications. Together, these activities provided a practical assessment of the system in a realistic surgical environment and generated data central to ongoing design decisions.

The December lab consisted of three independent development protocols, including a primary feasibility assessment focused on completing an intraperitoneal onlay mesh (IPOM) ventral hernia repair, a separate evaluation of monopolar scissors for energy delivery and cauterization, and a series of visualization and imaging assessments. Each protocol was designed to evaluate specific subsystems within a realistic in-vivo environment.

The in-vivo setting enabled an assessment of core system capabilities, including instrument articulation, visualization, system integration, and procedural workflow within a realistic surgical environment appropriate for system development. Data generated during the lab, along with structured surgeon feedback, are being incorporated into ongoing design refinement, verification planning, and system optimization efforts.